Pacira BioSciences, Inc. (PCRX) Covered Calls
Pacira BioSciences, Inc. (PCRX) is a specialty biopharmaceutical company focused on developing, manufacturing, and commercializing innovative, non-opioid pain management and regenerative health solutions. Headquartered in Tampa, Florida, the company is dedicated to improving patient outcomes by providing targeted, locally administered therapies that reduce reliance on traditional opioid-based pain relief in acute care and outpatient settings.
You can sell covered calls on Pacira BioSciences, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for PCRX (prices last updated Wed 11:25 AM ET):
| Pacira BioSciences, Inc. (PCRX) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 22.57 | +0.12 | 22.56 | 22.60 | 118K | 49 | 0.9 |
| Covered Calls For Pacira BioSciences, Inc. (PCRX) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 22.5 | 0.05 | 22.55 | -0.2% | -7.3% | |
| Apr 17 | 22.5 | 0.15 | 22.45 | 0.2% | 1.9% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Pacira’s business model is built around its proprietary DepoFoam drug delivery platform, which enables the sustained release of drugs over a prolonged period. This technology is the foundation of its commercial portfolio, which targets the musculoskeletal and postsurgical pain markets:
- EXPAREL (bupivacaine liposome injectable suspension): The company’s flagship product, EXPAREL is a long-acting local anesthetic used for postsurgical pain management. By providing days of pain control with a single dose, it serves as a critical tool for opioid-sparing protocols in hospitals and ambulatory surgery centers.
- ZILRETTA (triamcinolone acetonide extended-release injectable suspension): An intra-articular injection used for the management of knee pain associated with osteoarthritis. It utilizes proprietary microsphere technology to provide extended relief.
- iovera°: A handheld cryoanalgesia device that delivers focused, cold-based therapy to peripheral nerves, offering drug-free pain control.
The company is currently executing a "5x30" strategic plan, aiming to transition into a diversified, innovative biopharmaceutical organization by 2030 through pipeline advancement, including the development of PCRX-201, a gene therapy platform for osteoarthritis.
Competitive Landscape
Pacira operates in the highly competitive pharmaceutical and biotechnology sector, where it faces both direct and indirect competition:
- Heron Therapeutics: A direct competitor in the long-acting anesthetic space, specifically with its product ZYNRELEF.
- Large-Cap Pharma: Major companies like Pfizer and Johnson & Johnson are active in pain management research, representing significant indirect competition through their massive R&D resources and broad therapeutic reach.
- Broad Pain Market: The company faces ongoing competition from traditional, low-cost pain management approaches, including standard non-steroidal anti-inflammatory drugs (NSAIDs) and systemic opioids.
Strategic Outlook and Innovation
For 2026, Pacira is focused on maximizing the adoption of EXPAREL through expanding reimbursement coverage and navigating the NOPAIN Act landscape. Management is also prioritizing margin expansion and operational efficiencies, supported by upgraded large-scale manufacturing facilities. The company’s long-term growth is heavily tied to the clinical success of its pipeline, specifically the PCRX-201 gene therapy platform, as it seeks to redefine the standard of care for chronic musculoskeletal conditions.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | CTMX covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | PATH covered calls | |
| 3. | EEM covered calls | 8. | GLD covered calls | 3. | USO covered calls | |
| 4. | SPY covered calls | 9. | FXI covered calls | 4. | S covered calls | |
| 5. | IBIT covered calls | 10. | KWEB covered calls | 5. | HIMS covered calls | |
Want more examples? PCOR Covered Calls | PCT Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
